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Abstract
Renal cell carcinoma accounts for 85% of all solid renal tumors in adults. Nearly one quarter of
patients has distant metastasis at presentation while another 50% develop metastasis during follow-
up. A small percentage of these are solitary metastasis. We report here a case of solitary bone sternal
metastasis as an initial presentation of clear-cell renal cell carcinoma in a 56-year-old woman. The
prognosis for patients with metastasized renal cell carcinoma is poor; treatment of metastasis is
usually palliative and designed to provide comfort and pain relief. Palliative nephrectomy may be
considered for control of symptoms. Radical nephrectomy associated with metastatic bone tumor
resection is being tested to improve functional status and survival, especially when metastasis involves
supporting bones.
Introduction
Renal cell carcinoma (RCC) represents about 2% of all
adult malignant lesions [1]. It is the most common renal
neoplasm and accounts for 85% of all solid renal tumors
in adults [2]. The clear-cell variety is the most common
histologic subtype, accounting for 70% of all RCC [3].
Nearly 20-30% of patients with RCC have distant
metastasis at presentation [4], and of these, solitary bone
metastasis represents 1.6-3.6% [5]. We report here a caseof
solitary bone metastasis to the sternum as an initial
presentation of clear-cell renal carcinoma in a 56-year-old
woman.
Case presentation
A 56-year-old healthy Caucasian Brazilian woman pre-
sented with a six-month history of sternal pain and a two
month history of increase in volume of the region, without
phlogistic signs, fever, or urinary symptoms.
The patient was in good condition and her physical
examination was normal, except for a painful palpable
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occupying almost the entire body of the sternum. Her
hemogram, urea, creatinine, liver function tests, and
urinalysis were unchanged. Technetium-99 m methylene
diphosphonate (MDP) bone scanning showed uptake in
the sternal body (Figure 1). She was treated with anti-
inflammatory drugs, and instructed to return ten days
later, for new assessment. She did not return for the
follow-up.
Subsequently, the patient noticed increased local volume
and worsening pain, and she again sought medical care.
Computed tomography (CT) of the chest showed a soft-
tissue mass with heterogeneous contrast enhancement,
occupying almost all of the sternal body and extending to
the subcutaneous tissue, but with no evidence of lung
lesions or lymphadenopathy (Figure 2). Because of the
possibility that the sternal mass was a metastasis, a search
for a primary tumor was undertaken with mammography
and abdominal ultrasonography. Sonography showed an
exophytic left-sided renal mass measuring about 5 cm in
diameter, locally distorting the pyelocaliceal system,
without venous thrombus. The result suggested RCC.
Likewise, an abdominal CT scan following administration
of contrast medium revealed a heterogeneous and avidly
enhancing mass in the same location, with hypodense central areas indicative of cystic degeneration or necrosis.
The CT scan also revealed local distortion of the
pyelocaliceal system, without evidence of venous throm-
bus or lymphadenopathy (Figure 3).
Preoperative percutaneous biopsy guided by CT scan of
both the renal and sternal lesions showed histopathologic
diagnosis of clear-cell renal carcinoma. The patient was
planned for nephrectomy and radiotherapy of the sternal
lesion for palliation of the pain and reduction of the
tumor volume. The patient returned for follow-up assess-
ment six months later, complaining of left upper limb
paresy/paresthesia. The cervical spine MRI showed lesions
compatible with metastasis. She died six months later,
with generalized metastasis.
Discussion
The classic presentation of RCC comprising pain, flank
mass, and hematuria occurs in only 10% of cases [6].
Twenty to thirty-nine percent of patients with RCC are
asymptomatic, and the diagnosis is made incidentally
from a radiologic study obtained for other reasons [6].
Frequently, the first symptoms are from metastatic lesions
or paraneoplastic syndromes, including hypercalcemia,
erythrocytosis, and non-metastatic hepatocellular enzyme
elevation (Stauffer syndrome). Polyneuromyopathy, amy-
loidosis, anemia, fever, cachexia, weight loss, dermato-
myositis, and hypertension also are associated with RCC.
In 38-48% of patients with bone metastases, local pain led
to the search for and diagnosis of kidney tumors [5].
Figure 1. Metastatic bone disease. Bone scintigram shows
uptake in the sternal body.
Figure 2. Thoracic CT scan showing soft-tissue mass in
the sternum.
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metastases at diagnosis [7], 25% have locally advanced
disease, and 45% have localized disease (stages I and II)
[8]. Estimates show that about 60-70% of patients will
develop metastases during the course of their illness [9].
The most common sites of metastasis in RCC are the lung
(75% of cases), lymph nodes (36%), bones (20%), liver
(18%), skin (8%), and brain (8%) [10]. Solitary meta-
stases occur in less than 5% of cases of metastasized
disease [7]. Bone infiltration occurs in 50% of patients
with multiple organ metastasis, and 15-30% of these
lesions are solitary [5].
The tumor size, staging, and histopathologic grading of the
nuclei of the tumor are important factors determining the
likelihood that metastatic disease develops [11]. Nuclear
grading according to the Fuhrman classification system
[12] is widely accepted and has been shown to confer
prognostic significance. A sharp increase in metastases and
a decrease in survival have been noted for patients with
lesions that are nuclear grade 3 or 4 [13]. TNM tumor
staging is even more predictive than the Fuhrman system:
capsular transgression defines a T3 lesion, and T3 or T4
lesions are associated with a significant increase in
metastases and a decrease in survival [4].
Nephrectomy remains the standard management for
localized disease and now has a role in selected patients
with metastatic disease. It may be justified in patients with
metastatic disease to improve quality of life or local
symptoms and possibly to increase survival [6]. Palliative
nephrectomy may be considered for alleviation of pain,
hemorrhage, malaise, hypercalcemia, erythrocytosis, or
hypertension in patients with metastatic disease [6].
However, it is not justified as a means to induce
spontaneous tumor regression as this occurs in less than
1% of cases, most frequently in the lungs [14]. Preopera-
tive embolization can provide symptomatic relief and
reduce intraoperative bleeding in large tumors. Treatment
of metastasis is usually palliative and aims to provide
patient comfort by means of pain relief. Radiation therapy
is sometimes used for palliation and is an option to
alleviate bone pain associated with metastasis.
Resection of isolated bone metastases together with
radical nephrectomy has been advocated when the lesions
are larger than 2-3 cm, have destroyed more than 50% of
the cortex, or occurs in sustentation bones [9]. Treatment
aims to prevent pathological fractures, alleviate pain,
increase functional mobility, and prolong survival.
Surgical excision of a solitary metastasis may improve
survival, especially in cases of lung and bone metastases
[4]. Kozlowski [5] showed that two-year survival after
surgical excision of solitary synchronous metastatic
lesions was 22%.
Immunotherapy of metastatic RCC gave durable remis-
sions in only a minority of patients; the response rate to
immunotherapy with interleukin-2 or interferon-a was
only 20% [15]. Currently, less than 5% of metastatic RCCs
respond to chemotherapy. However, newer agents such as
sorafenib and sunitinib have emerged as a promising
treatment. These tyrosine kinase inhibitors that specifi-
cally inhibit receptors for both vascular endothelial
growth factor and platelet-derived growth factor have
been shown to improve progression-free survival in
metastatic RCC [16].
Conclusion
Despite technological advances that ought to ensure the
early identification of RCC, about 25-30% of patients have
metastases at presentation. The prognosis of these patients
is poor, especially due to the lack of effectiveness of
radiation and chemotherapy. New immunomodulatory
agents have been tested, but successes have been infre-
quent and short-lived. Radical nephrectomy together with
resection of metastatic bone tumors and radiation therapy
are being tested to improve functional status and survival,
especially when metastasis involves supporting bones.
These methods can contribute to long-term survival in
some patients.
Figure 3. Abdominal CT scan demonstrating a left-sided
mass in a 56-year-old woman. The mass was well-defined,
exophytic—appearing to arise from the cortex—and
heterogeneously and avidly enhancing. (A) Corticomedullary
and (B) Nephrographic phases show typical hypervascularity
of the tumor. (C) Coronal and (D) Sagittal multiplanar
reformatation during excretory phase.
Page 3 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:9045 http://casesjournal.com/casesjournal/article/view/9045Abbreviations
CT, computed tomography; RCC, renal cell carcinoma.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RRB conceived the study. TCT, FCC and RFC performed
the literature review. RRB, GZ and EM edit and coordi-
nated the manuscript. All authors read and approved the
final manuscript.
References
1. Prando A, Prando D, Prando P: Renal cell carcinoma: unusual
imaging manifestations. Radiographics 2006, 26:233-244.
2. LinSP,BierhalsAJ,LewisJSJr:BestcasesfromtheAFIPMetastatic
renal cell carcinoma. Radiographics 2007, 27:1801-1807.
3. Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD,
Dalrymple NC, Chintapalli KN: Common and uncommon
histologic subtypes of renal cell carcinoma: imaging spec-
trum with pathologic correlation. Radiographics 2006, 26:1795-
1806.
4. Griffin N, Gore ME, Sohaib SA: Imaging in metastatic renal cell
carcinoma. AJR Am J Roentgenol 2007, 189:360-370.
5. Kozlowski JM: Management of distant solitary recurrence in
the patient with renal cancer. Contralateral kidney and other
sites. Urol Clin North Am 1994, 21:601-624.
6. Curti BD: Renal cell carcinoma. JAMA 2004, 292:97-100.
7. Sadler GJ, Anderson MR, Moss MS, Wilson PG: Metastases from
renal cell carcinoma presenting as gastrointestinal bleeding:
two case reports and a review of the literature. BMC
Gastroenterol 2007, 7:4.
8. Azam F, Abubakerr M, Gollins S: Tongue metastasis as an initial
presentation of renal cell carcinoma: a case report and
literature review. J Med Case Reports 2008, 2:249.
9. van der Poel HG, Roukema JA, Horenblas S, van Geel AN,
Debruyne FM: Metastasectomy in renal cell carcinoma: A
multicenter retrospective analysis. Eur Urol 1999, 35:197-203.
10. Maldazys JD, deKernion JB: Prognostic factors in metastatic
renal carcinoma. J Urol 1986, 136:376-379.
11. Scatarige JC, Sheth S, Corl FM, Fishman EK: Patterns of recurrence
in renal cell carcinoma: manifestations on helical CT. AJR Am J
Roentgenol 2001, 177:653-658.
12. Chae EJ, Kim JK, Kim SH, Bae SJ, Cho KS: Renal cell carcinoma:
analysis of postoperative recurrence patterns. Radiology 2005,
234:189-196.
13. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of
morphologic parameters in renal cell carcinoma. Am J Surg
Pathol 1982, 6:655-663.
14. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM:
Renal cell carcinoma: diagnosis, staging, and surveillance. AJR
Am J Roentgenol 2008, 191:1220-1232.
15. Snow RM, Schellhammer PF: Spontaneous regression of meta-
static renal cell carcinoma. Urology 1982, 20:177-181.
16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J:
Survival and prognostic stratification of 670 patients with
advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
Do you have a case to share?
Submit your case report today
￿ Rapid peer review
￿ Fast publication
￿ PubMed indexing
￿ Inclusion in Cases Database
Any patient, any case, can teach us
something
www.casesnetwork.com
Page 4 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:9045 http://casesjournal.com/casesjournal/article/view/9045